University Hospital, Caen
Pierre-Marie MORICE, PharmD, PhD
Although lenalidomide (LEN) have proved effective in treating many cancers, few patients receiving LEN may experience rare but life-threatening adverse events such as Acute Lymphoblastic Leukaemia (ALL). Today, data about ALL are scarce. The objective was to investigate reports of ALL adverse events related to LEN in patients with cancer using the World Health Organization (WHO) pharmacovigilance database.
Cancer
Lenalidomide
| Study Type : | OBSERVATIONAL |
| Estimated Enrollment : | 300 participants |
| Official Title : | Acute Lymphoblastic Leukaemia Related to Lenalidomide in Patients With Cancer: an Observational and Retrospective Study Using the WHO's Pharmacovigilance Database |
| Actual Study Start Date : | 2024-02-01 |
| Estimated Primary Completion Date : | 2024-02-15 |
| Estimated Study Completion Date : | 2024-03-31 |
Information not available for Arms and Intervention/treatment
| Ages Eligible for Study: | 18 Years |
| Sexes Eligible for Study: | ALL |
| Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
chu's CAE N
Caen, France, 14033